Insights into Transglutaminase 2 Function Gained from Genetically Modified Animal Models
Reference116 articles.
1. Abedin M, Tintut Y, Demer LL (2004) Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 24(7):1161–1170
2. Bailey CD, Johnson GV (2006) The protective effects of cystamine in the R6/2 Huntington’s disease mouse involve mechanisms other than the inhibition of tissue transglutaminase. Neurobiol Aging 27(6):871–879
3. Bailey CD, Graham RM, Nanda N, Davies PJ, Johnson GV (2004) Validity of mouse models for the study of tissue transglutaminase in neurodegenerative diseases. Mol Cell Neurosci 25(3):493–503
4. Bakker EN, Pistea A, Spaan JA, Rolf T, de Vries CJ, van Rooijen N, Candi E, VanBavel E (2006) Flow-dependent remodeling of small arteries in mice deficient for tissue-type transglutaminase: possible compensation by macrophage-derived factor XIII. Circ Res 99(1):86–92
5. Balajthy Z, Csomós K, Vámosi G, Szántó A, Lanotte M, Fésüs L (2006) Tissue-transglutaminase contributes to neutrophil granulocyte differentiation and functions. Blood 108(6):2045–2054